CytoCore, Inc. is a publicly traded biotechnology company (BB:CYCR) that is developing a proteomic-based method of screening and diagnosis for endometrial and cervical cancer. The company's major product is called the InPath™ System and is comprised of four distinct components: the e Collector™, protein-based biochemical cocktails and Slide Based Tests, the AIPS™ microscope platform, and a drug delivery system for treating cervical lesions. CytoCore's InPath™ System is expected to provide a method for cervical cancer screening in countries where the standard Pap test is not available and make the Pap test more accurate in countries where it is currently used. The InPath™ System also offers a simple and cost-effective method to screen women for endometrial cancer.
The science of medical diagnostics has advanced significantly during the past decade. Much of this improvement has come as a result of new knowledge of the human genome and related proteins, which form the foundation of cell biology and disease at the molecular level. CytoCore's goal is to utilize this biomolecular research as a basis to develop screening and diagnostic testing products for cancer and cancer-related diseases. We believe that the success of CytoCore's products will improve patient care through more accurate test performance, wider test availability and more cost effective service delivery.
CytoCore is in a position to revolutionize women's reproductive healthcare, specifically cervical and uterine cancer screening and diagnostics, on a global scale through its InPath™ System. Based upon a revolutionary in-vitro diagnostic application of proteomic (protein) detection technology, the InPath™ System is designed to detect, at the earliest possible stage, cancer and cancer-related diseases of the cervix and uterus.
It is widely accepted that the most effective means of fighting cancer is early detection when treatment is most likely to be effective. In the case of cervical and endometrial cancer, early molecular changes can be detected and treated before they develop into cancer. CytoCore's technology has the potential to expand the applications for pre-cancer screening because it reduces human error and provides the patient with a faster test result in addition to improved accuracy.
Many studies have shown that 70 - 80% of a person's entire healthcare expenditures over their whole life occur in the last 4 - 6 months of life. As a result, more and more attention is being given to catching a disease condition early before it gets out of hand and becomes a potentially fatal illness. As part of this shift in emphasis, the FDA recently announced that 60% of its approvals in the coming period would be for "diagnostic related products." These biomolecular screening, diagnostic, and treatment products are being developed to catch disease states early so they can be dealt with before they become life threatening and expensive to treat. CytoCore is designing and developing its products to satisfy this paradigm shift. Moreover, the company's screening and diagnostic products are also suitable for overseas markets (China, India, ASEAN, Latin America, and Africa & the Middle East), where they do not have adequate laboratory infrastructures to accommodate state of the art medical testing.
414 North Orleans Street Suite 502 Chicago Illinois 60610 United States of America
CytoCore, Inc. is a publicly traded biotechnology company (BB:CYCR) that is developing a proteomic-based method of screening and diagnosis for endometrial and cervical cancer. The company's major prod...
Cervical Cancer Cervical cancer is a malignant neoplasm of the cervix uteri or cervical area. Symptoms include vaginal bleeding, but may not present until later stages of the cancer. Cervical cancer can be treated using surgery (including local excision) in early stages...